SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19

被引:222
|
作者
Grifoni, Alba [1 ]
Sidney, John [1 ]
Vita, Randi [1 ]
Peters, Bjoern [1 ,2 ]
Crotty, Shane [1 ,2 ]
Weiskopf, Daniela [1 ]
Sette, Alessandro [1 ,2 ]
机构
[1] La Jolla Inst Immunol LJI, Ctr Infect Dis & Vaccine Res, La Jolla, CA 92037 USA
[2] Univ Calif San Diego UCSD, Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92037 USA
关键词
HLA CLASS-I; COMPREHENSIVE ANALYSIS; VIRUS; ANTIGEN; IMMUNODOMINANCE; BINDING; IMMUNOPREVALENCE; IDENTIFICATION; RECOGNITION; MUTATIONS;
D O I
10.1016/j.chom.2021.05.010
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Over the past year, numerous studies in the peer reviewed and preprint literature have reported on the virological, epidemiological and clinical characteristics of the coronavirus, SARS-CoV-2. To date, 25 studies have investigated and identified SARS-CoV-2-derived T cell epitopes in humans. Here, we review these recent studies, how they were performed, and their findings. We review how epitopes identified throughout the SARS-CoV2 proteome reveal significant correlation between number of epitopes defined and size of the antigen provenance. We also report additional analysis of SARS-CoV-2 human CD4 and CD8 T cell epitope data compiled from these studies, identifying 1,400 different reported SARS-CoV-2 epitopes and revealing discrete immunodominant regions of the virus and epitopes that are more prevalently recognized. This remarkable breadth of epitope repertoire has implications for vaccine design, cross-reactivity, and immune escape by SARS-CoV-2 variants.
引用
收藏
页码:1076 / 1092
页数:17
相关论文
共 50 条
  • [1] SARS-CoV-2 human T cell epitopes Adaptive immune response against COVID-19 (vol 29, pg 1076, 2021)
    Grifoni, Alba
    Sidney, John
    Vita, Randi
    Peters, Bjoern
    Crotty, Shane
    Weiskopf, Daniela
    Sette, Alessandro
    CELL HOST & MICROBE, 2022, 30 (12) : 1788 - 1788
  • [2] The T cell immune response against SARS-CoV-2
    Paul Moss
    Nature Immunology, 2022, 23 : 186 - 193
  • [3] The T cell immune response against SARS-CoV-2
    Moss, Paul
    NATURE IMMUNOLOGY, 2022, 23 (02) : 186 - 193
  • [4] Prediction of the SARS-CoV-2 Derived T-Cell Epitopes? Response Against COVID Variants
    Tahir, Hassam
    Khan, Muhammad Shahbaz
    Ahmed, Fawad
    Albarrak, Abdullah M.
    Qasem, Sultan Noman
    Ahmad, Jawad
    CMC-COMPUTERS MATERIALS & CONTINUA, 2023, 75 (02): : 3517 - 3535
  • [5] Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases
    Tarke, Alison
    Sidney, John
    Kidd, Conner K.
    Dan, Jennifer M.
    Ramirez, Sydney, I
    Yu, Esther Dawen
    Mateus, Jose
    Antunes, Ricardo da Silva
    Moore, Erin
    Rubiro, Paul
    Methot, Nils
    Phillips, Elizabeth
    Mallal, Simon
    Frazier, April
    Rawlings, Stephen A.
    Greenbaum, Jason A.
    Peters, Bjoern
    Smith, Davey M.
    Crotty, Shane
    Weiskopf, Daniela
    Grifoni, Alba
    Sette, Alessandro
    CELL REPORTS MEDICINE, 2021, 2 (02)
  • [6] Adaptive immunity to SARS-CoV-2 and COVID-19
    Sette, Alessandro
    Crotty, Shane
    CELL, 2021, 184 (04) : 861 - 880
  • [7] Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses
    Ravindran, Resmi
    McReynolds, Cindy
    Yang, Jun
    Hammock, Bruce D.
    Ikram, Aamer
    Ali, Amna
    Bashir, Adnan
    Zohra, Tanzeel
    Chang, W. L. William
    Hartigan-O'Connor, Dennis J.
    Rashidi, Hooman H.
    Khan, Imran H.
    PLOS ONE, 2021, 16 (07):
  • [8] Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2
    Ameratunga, Rohan
    Woon, See-Tarn
    Steele, Richard
    Lehnert, Klaus
    Leung, Euphemia
    Brooks, Anna E. S.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (06) : 557 - 565
  • [9] The immune response to SARS-CoV-2 and COVID-19 immunopathology -- Current perspectives
    Boechat, J. L.
    Chora, I.
    Morais, A.
    Delgado, L.
    PULMONOLOGY, 2021, 27 (05): : 423 - 437
  • [10] Immune response to SARS-CoV-2 in severe disease and long COVID-19
    Sumi, Tomonari
    Harada, Kouji
    ISCIENCE, 2022, 25 (08)